Comparison · NCT02349477-dba93366
Gabapentin vs Placebo: Percent of Subjects With no Heavy Drinking Days (PSNHDD)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Gabapentin vs Placebo: Percent of Subjects With no Heavy Drinking Days (PSNHDD). Trial comparisons, record NCT02349477-dba93366. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02349477-dba93366
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.273 | 0.163 | 0.418 | wilson | |
| Risk in group 2 | 0.087 | 0.0343 | 0.203 | wilson | |
| Risk difference, group 1 minus group 2 | 0.186 | 0.0262 | 0.341 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 3.14 | 1.09 | 8.99 | log | |
| Odds ratio, group 1 over group 2 | 3.94 | 1.16 | 13.4 | log | |
| Number needed to treat, for one more participant with the outcome on Gabapentin than on Placebo | 5.38 | 2.93 | 38.2 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Gabapentin | Gabapentin up to 1200 mg per day in 3 divided doses~Gabapentin: gaba potentiating medication | 12 | 44 | OG000 |
| Group 2 | Placebo | matching placebo~Placebo: a pill that looks exactly like the active medication but does not contain medication | 4 | 46 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Percent of Subjects With no Heavy Drinking Days (PSNHDD)
- Description
The primary dependent variable will be the percent of subjects with no heavy drinking days (4 or more standard drinks for women and 5 or more standard drinks for men). Participants will report their daily alcohol use with using a daily calendar. No heavy drinking days is corrected for %dCDT.
- Time frame
- 4 months
- Population
Source ClinicalTrials.gov
Trial
- Title
- Gabapentin for Alcohol Relapse Prevention
- NCT number
- NCT02349477
- Phases
- PHASE2
- Conditions
- Alcohol Use Disorder, Alcohol Withdrawal
- Interventions
- Gabapentin, Placebo
- Lead sponsor
- Medical University of South Carolina
- Results first posted
- 2019-11-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02349477?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02349477-dba93366